ProCE Banner Activity

The Evolving Disease-Modifying Therapy Landscape in Multiple Sclerosis

Clinical Thought

Expert commentary on the wide variety of current and emerging disease-modifying therapies available for multiple sclerosis, including the clinical need for a personalized approach to treatment choice.

Released: January 22, 2025

Expiration: January 21, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Jiwon Oh, MD, PhD, FRCPC

Medical Director, Barlo Multiple Sclerosis Program
Waugh Family Chair in MS Research
Staff Neurologist, St. Michael’s Hospital
Scientist, Keenan Research Centre of the Li Ka Shing Knowledge Institute
Associate Professor, Division of Neurology
University of Toronto
Toronto, Ontario, Canada

Jiwon Oh, MD, PhD, FRCPC: consultant/advisor/speaker: Biogen Idec, EMD Serono, Lilly, Horizon Therapeutics, Novartis, Roche, Sanofi/Genzyme.